The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.40
Ask: 66.00
Change: -1.50 (-2.27%)
Spread: 2.60 (4.101%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cancellation of trading of Yourgene Shares

11 Sep 2023 07:55

RNS Number : 9939L
Novacyt S.A.
11 September 2023
 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

De-listing and cancellation of trading of Yourgene Shares

 

Paris, France and Eastleigh, UK - 11 September 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today's announcement by Yourgene Health plc ("Yourgene"), in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the "Acquisition"), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").

 

Further to the announcement made by Yourgene on 8 September 2023 that the Scheme has now become Effective in accordance with its terms, Yourgene has today announced that, following an application to the London Stock Exchange, the admission to trading on AIM of Yourgene Shares has been cancelled with effect from 7.00 a.m. today, 11 September 2023.

 

Yourgene's full announcement can be found here: https://polaris.brighterir.com/public/yourgenehealth/news/rns/story/wkjon2r

 

Contacts

 

Novacyt SA

+44 (0)23 8074 8830

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

Numis (Financial Adviser and Joint Broker to Novacyt and Financial Adviser to Novacyt UK)

+44 (0)20 7260 1000

Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker to Novacyt)

+44 (0)20 3470 0470

 

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

 +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)

Stephanie Cuthbert / Anna Dunphy / Phillip Marriage

+44 (0)20 7933 8780

novacyt@walbrookpr.com

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio of in vitro and molecular diagnostic tests for a wide range of infectious diseases, enabling faster, more accurate, accessible testing to improve healthcare outcomes. The Company provides customers with a seamless sample-to-result workflow using its integrated and scalable instrumentation/solutions. The Company specialises in the design, manufacture, and supply of real-time PCR kits, reagents and a full range of laboratory and qPCR instrumentation for molecular biology research and clinical use. Novacyt offers one of the world's most varied and comprehensive range of qPCR assays, covering human, veterinary, biodefence, environmental, agriculture and food testing.

 

Novacyt is headquartered in Vélizy in France with offices in Stokesley and Eastleigh, UK, and is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

 

Building on our expertise in genomic technology, Yourgene's Ranger® Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger® Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

 

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFLRADILLIV
Date   Source Headline
18th Mar 20226:00 pmRNSDirector/PCA Dealing
15th Mar 20222:30 pmRNSDirector/PDMR Shareholding
11th Mar 20228:00 amRNSHoldings in Company
1st Mar 20221:00 pmRNSLiquidity Agreement Update and Total Voting Rights
18th Feb 20224:05 pmRNSHoldings in Company
17th Feb 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
15th Feb 20224:00 pmRNSHoldings in Company
4th Feb 20227:00 amRNSLong Term Incentive Plan
1st Feb 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20227:00 amRNSStrategy and Full Year 2021 Trading Update
4th Jan 20224:30 pmRNSLiquidity Agreement and Total Voting Rights
1st Dec 20212:30 pmRNSTotal Voting Rights
26th Nov 20217:00 amRNSApproval of COVID-19 test under CTDA legislation
2nd Nov 20217:00 amRNSValidation of COVID-19 tests in the UK under CTDA
1st Nov 20215:30 pmRNSLiquidity Agreement and Total Voting Rights
19th Oct 20214:15 pmRNSResults of annual general meeting
1st Oct 20212:30 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSR&D update
29th Sep 20215:00 pmRNSNotice of AGM
29th Sep 20217:00 amRNSNotice of rescheduled AGM
27th Sep 20217:00 amRNSHalf year 2021 results
16th Sep 20217:00 amRNSProposed accounting treatment of DHSC dispute
13th Sep 20217:00 amRNSAGM voting
1st Sep 202111:30 amRNSLiquidity Agreement and Total Voting Rights
20th Aug 20217:00 amRNSNotice of AGM
18th Aug 20217:00 amRNSHalf Year Update
5th Aug 20217:00 amRNSNotice of investor meeting
2nd Aug 20211:30 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSDavid Allmond to be CEO, Graham Mullis to retire
6th Jul 20212:40 pmRNSDirector/PDMR Shareholding
1st Jul 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Jun 20217:00 amRNSPublication of Annual Report
29th Jun 20217:00 amRNSExpansion of PathFlow COVID-19 LFT portfolio
22nd Jun 20217:00 amRNSFull year 2020 results and update on strategy
18th Jun 20217:00 amRNSUpdate on Notice of 2020 Full Year Results
3rd Jun 20217:00 amRNSLaunch of two new PCR COVID-19 assays
1st Jun 20212:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20217:00 amRNSLaunch of VersaLab Portable
21st May 20217:00 amRNSDHSC Dispute Update
17th May 20217:00 amRNSInclusion of SNPsig in the NHS England Framework
4th May 20211:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSNovacyt donates 1 million COVID-19 tests to UNICEF
23rd Apr 20217:00 amRNSR&D and UK operational update
22nd Apr 20217:00 amRNSNotice of Results
9th Apr 202112:30 pmRNSTrading Update
1st Apr 20211:40 pmRNSTotal Voting Rights
24th Mar 20217:00 amRNSLaunch of VariPLEX CE-Mark test
17th Mar 20217:11 amRNSLaunch of mobile processing laboratories
15th Mar 20214:45 pmRNSHoldings in Company
15th Mar 202111:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.